Undisclosed GI Program(s)
Gastrointestinal Diseases (e.g., Inflammatory Bowel Disease)
PreclinicalActive
Key Facts
Indication
Gastrointestinal Diseases (e.g., Inflammatory Bowel Disease)
Phase
Preclinical
Status
Active
Company
About Particella
Particella is pioneering the development of oral mRNA medicines using a proprietary lipid nanoparticle technology aimed at the intestinal epithelium. Founded in 2021, the company is in the preclinical stage, seeking to overcome the significant challenge of orally delivering nucleic acids, which are typically degraded in the gut. Its platform promises repeatable dosing, a non-immunogenic profile, and a patient-friendly administration route compared to injectable alternatives. If successful, this technology could unlock a new class of treatments for a wide range of gastrointestinal disorders and potentially enable systemic delivery via the gut.
View full company profile